Tags

Type your tag names separated by a space and hit enter

Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus.
J Oral Pathol Med. 1994 Apr; 23(4):172-7.JO

Abstract

The purpose of this study was to evaluate the effect of levamisole on the immune system of patients with recurrent aphthous ulcers (RAU) or oral lichen planus (OLP) in an open trial. Lymphocyte subsets, serum immunoglobulins, and circulating immune complexes (CIC) in patients with RAU or OLP and in normal control subjects were determined by an indirect immunofluorescence (IIF) technique with monoclonal anti-lymphocyte antibodies, by single radial immunodiffusion, and by precipitation with 3% polyethylene glycol, respectively. In addition, the anti-nuclear antibodies (ANA) and anti-basal cell antibodies (anti-BCA) in sera were detected by an IIF technique. We found a significant improvement in clinical symptoms and normalization of the decreased CD4/CD8 ratio in RAU patients after levamisole treatment. Moreover, the decreased CD4/CD8 ratio, which persisted until the remission stage in the untreated RAU patients, reverted to normal in the active late stage in the levamisole-treated patients. This reversion of aberrant cellular immunity in an earlier stage of the ulcer cycle may explain why RAU patients experience symptom improvement after levamisole treatment. Although RAU patients treated with levamisole for 1 to 3 or 4 months still had higher than normal levels of CIC and serum immunoglobulins, the levels of their IgA and IgM returned to normal values after 4 months of levamisole treatment. The serum ANA detected in 6 patients with RAU and 3 patients with erosive OLP disappeared after 1-22 months of levamisole treatment. The disappearance of serum anti-BCA was also observed in 50% of the anti-BCA-positive patients with erosive OLP after 3-13 months of levamisole treatment.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

School of Dentistry, National Taiwan University, Taipei, ROC.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7913970

Citation

Sun, A, et al. "Immunomodulation By Levamisole in Patients With Recurrent Aphthous Ulcers or Oral Lichen Planus." Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, vol. 23, no. 4, 1994, pp. 172-7.
Sun A, Chiang CP, Chiou PS, et al. Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. J Oral Pathol Med. 1994;23(4):172-7.
Sun, A., Chiang, C. P., Chiou, P. S., Wang, J. T., Liu, B. Y., & Wu, Y. C. (1994). Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 23(4), 172-7.
Sun A, et al. Immunomodulation By Levamisole in Patients With Recurrent Aphthous Ulcers or Oral Lichen Planus. J Oral Pathol Med. 1994;23(4):172-7. PubMed PMID: 7913970.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. AU - Sun,A, AU - Chiang,C P, AU - Chiou,P S, AU - Wang,J T, AU - Liu,B Y, AU - Wu,Y C, PY - 1994/4/1/pubmed PY - 1994/4/1/medline PY - 1994/4/1/entrez SP - 172 EP - 7 JF - Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology JO - J. Oral Pathol. Med. VL - 23 IS - 4 N2 - The purpose of this study was to evaluate the effect of levamisole on the immune system of patients with recurrent aphthous ulcers (RAU) or oral lichen planus (OLP) in an open trial. Lymphocyte subsets, serum immunoglobulins, and circulating immune complexes (CIC) in patients with RAU or OLP and in normal control subjects were determined by an indirect immunofluorescence (IIF) technique with monoclonal anti-lymphocyte antibodies, by single radial immunodiffusion, and by precipitation with 3% polyethylene glycol, respectively. In addition, the anti-nuclear antibodies (ANA) and anti-basal cell antibodies (anti-BCA) in sera were detected by an IIF technique. We found a significant improvement in clinical symptoms and normalization of the decreased CD4/CD8 ratio in RAU patients after levamisole treatment. Moreover, the decreased CD4/CD8 ratio, which persisted until the remission stage in the untreated RAU patients, reverted to normal in the active late stage in the levamisole-treated patients. This reversion of aberrant cellular immunity in an earlier stage of the ulcer cycle may explain why RAU patients experience symptom improvement after levamisole treatment. Although RAU patients treated with levamisole for 1 to 3 or 4 months still had higher than normal levels of CIC and serum immunoglobulins, the levels of their IgA and IgM returned to normal values after 4 months of levamisole treatment. The serum ANA detected in 6 patients with RAU and 3 patients with erosive OLP disappeared after 1-22 months of levamisole treatment. The disappearance of serum anti-BCA was also observed in 50% of the anti-BCA-positive patients with erosive OLP after 3-13 months of levamisole treatment.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0904-2512 UR - https://www.unboundmedicine.com/medline/citation/7913970/Immunomodulation_by_levamisole_in_patients_with_recurrent_aphthous_ulcers_or_oral_lichen_planus_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0904-2512&date=1994&volume=23&issue=4&spage=172 DB - PRIME DP - Unbound Medicine ER -